Osiris Therapeutics, Inc. (OSIR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report


Shutterstock photo

Osiris reported third quarter 2014 earnings of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.05 per share and the break-even results in the year-ago quarter. Revenues were $17.2 million, surpassing the Zacks Consensus Estimate of $15 million and increasing 150% y-o-y and 29.3% sequentially. Osiris' Biosurgery segment has been gaining traction over the past few quarters. The company's increased sales effort has started paying off. We are also positive on the company's sale of its ceMSC business which has not only brought in cash for Osiris in the form of an upfront payment but will also bring in royalties. While encouraged by the company's progress with its Biosurgery business, we remain concerned about the dependence on a single segment for growth. We remain Neutral on the stock.


Columbia, MD-based Osiris Therapeutics, Inc. focuses on the development, manufacture and sale of biologic products which have been developed to promote the body's natural healing process and improve surgical outcomes. Currently marketed products include Grafix, Ovation, OvationOS and Cartiform for tissue repair.

In Oct 2013, Osiris sold its culture-expanded mesenchymal stem cell (ceMSC) business including Prochymal to a wholly-owned subsidiary of Mesoblast Limited for up to $100 million. Osiris will also be entitled to receive single to low double-digit royalties on sales of products derived from the ceMSC technology. Osiris has also retained a license to all transferred intellectual property necessary to run its other businesses.

Osiris generates revenues from the Biosurgery segment, collaborative agreements, government contracts and research licenses. Total revenues came in at $24.3 million in 2013, up from $7.8 million in 2012.

Osiris Therapeutics, Inc. (OSIR): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OSIRIS THERAPTC (OSIR): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Stocks

More from Zacks.com




Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com